KRAS and colorectal carcinoma: The work of Gasch et al. points to considerable intra- and interpatient heterogeneity of EGFR expression and genetic alterations in EGFR, KRAS, and PIK3CA, thus possibly explaining the variable response rates to EGFR inhibition in patients with CRC [73].